NCT02197767View on ClinicalTrials.gov

Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Fibrillary Glomerulonephritis
Interventions
DRUG

rituximab

1000 mg infusion

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER

NCT02197767 - Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis | Biotech Hunter | Biotech Hunter